A5079594258- SARS-CoV-2 and COVID-19 Research
- Renal Transplantation Outcomes and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- COVID-19 Clinical Research Studies
- Renal Diseases and Glomerulopathies
- Otitis Media and Relapsing Polychondritis
- Drug-Induced Adverse Reactions
- Immunotherapy and Immune Responses
- Vasculitis and related conditions
- Gut microbiota and health
- Cancer Immunotherapy and Biomarkers
- Polyomavirus and related diseases
- Clostridium difficile and Clostridium perfringens research
- Central Venous Catheters and Hemodialysis
- Cardiac Imaging and Diagnostics
- Diabetes Treatment and Management
- Acute Kidney Injury Research
- Renal and Vascular Pathologies
- Complement system in diseases
- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Microbial Metabolites in Food Biotechnology
- Immunodeficiency and Autoimmune Disorders
- Pancreatic function and diabetes
- Chronic Kidney Disease and Diabetes
Royal Adelaide Hospital
2019-2025
Edinburgh Royal Infirmary
2024
Central Adelaide Local Health Network
2023
The University of Adelaide
2021-2023
Women's and Children's Health Network
2023
Camden and Campbelltown Hospitals
2021
St Vincent's Hospital Sydney
2021
Box Hill Hospital
2021
Monash University
2021
Western Sydney University
2021
Background: Failure to develop protective immunity in response vaccination is common among kidney transplant recipients, rendering them susceptible severe infection. Novel strategies are required. Here, we investigated the potential of mechanistic-target-of-rapamycin (mTOR) inhibitors improve vaccine responses. Methods: Humoral and cellular responses primary COVID-19 (ChAdOx1 or BNT162b2) were assessed for recipients receiving mTOR inhibitor-based (mTOR inhibitor, mycophenolate,...
Kidney transplant recipients (KTRs) are highly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease 2019 (COVID-19). The 28-day case mortality for KTRs is 24%, mounting evidence suggests poor immunogenicity clinical effectiveness of vaccines in this group.1Phanish M. Ster I.C. Ghazanfar A. et al.Systematic review meta-analysis COVID-19 kidney recipients, the South West London Transplant Network experience.Kidney Int Rep. 2021; 6: 574-585Google...
Resistance to rituximab B-cell depletion therapy is a clinically pertinent adverse sequela that can have significant implications for the treatment of immune-mediated glomerular diseases. The true incidence resistance remains unknown; however, it an increasingly recognized complication. typically presents with suboptimal response, rapid reconstitution, and relapsing disease course. Although diverse mechanisms resulting in are ongoing topics research, both primary secondary been identified as...
Kidney transplant recipients are at an increased risk of hospitalisation and death from SARS-CoV-2 infection, standard two-dose vaccination schedules typically inadequate to generate protective immunity. Gut dysbiosis, which is common among kidney known effect systemic immunity, may be a contributing factor lack vaccine immunogenicity in this at-risk cohort. The gut microbiota modulates responses, with the production immunomodulatory short-chain fatty acids by bacteria such as...
Introduction Kidney transplant recipients (KTRs) are at an increased risk of hospitalisation and death from COVID-19. Vaccination against SARS-CoV-2 is our primary mitigation strategy, yet vaccine effectiveness in KTRs suboptimal. Strategies to enhance efficacy therefore required. Current evidence supports the role gut microbiota shaping immune response vaccination. Gut dysbiosis common a potential contributor impaired COVID-19 responses. We hypothesise that dietary fibre supplementation...
Abstract Inadequate immune response to vaccination is a long-standing problem faced by immunosuppressed kidney transplant recipients (KTRs), requiring novel strategies improve vaccine efficacy. In this study, the potential of mechanistic target rapamycin inhibitors (mTORi) T cell responses COVID-19 was investigated. Following primary with adenoviral (ChAdOx1) or mRNA (BNT162b2) vaccines, KTRs receiving demonstrated greater than those healthy individuals, characterized increased frequencies...
Abstract Kidney transplant recipients are at an increased risk of severe COVID-19-associated hospitalisation and death. Vaccination has been a key public health strategy to reduce disease severity infectivity, but the effectiveness COVID vaccines is markedly reduced in kidney recipients. Urgent strategies enhance vaccine efficacy needed. Methods: RIVASTIM-rapamycin multicentre, randomised, controlled trial examining effect immunosuppression modification prior third dose COVID-19 who have...
The long-term effects of arteriovenous fistula (AVF) ligation on cardiovascular structure following kidney transplantation remain uncertain. A prospective randomized, controlled trial (RCT) examined the effect AVF at 6 months magnetic resonance imaging (CMR)-derived parameters in 27 transplant recipients compared with controls. mean decrease left ventricular mass (LVM) 22.1 g (95% CI, 15.0 to 29.1) was observed an increase 1.2 -4.8 7.2) control group (P<0.001). We conducted a follow-up...
Abstract Objectives Patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) are at increased long-term risk of cardiometabolic diseases. The prevalence obesity in AAV has not been well documented. We aimed to characterise change body weight following a diagnosis active and determine the factors for this. Methods examined data from single-centre registry patients AAV, diagnosed between 2003 2023. evaluated changes BMI diagnosis. Using linear regression, we...
The history of renal replacement therapy (RRT) for end-stage kidney disease (ESKD) started in 1960 and has reached, these six decades, goals initially unforeseen. This report describes two patients who commenced dialysis at the age 17 27, 53 45 years, respectively, whereby modality RRT was mostly form home haemodialysis. patients, distant parts world, Australia Croatia, highlights not only advances made over time, to significantly delay onset reduce morbidity mortality associated with ESKD,...
The development of vaccines against SARS-CoV2 has been a key public health response to the COVID-19 pandemic. However, since their introduction, there have reports anaphylactic reactions in individuals with history allergic other vaccines, excipients or COVID vaccines.A dedicated adult vaccine allergy clinic standardised testing protocol was set up investigate safety and suitability available Australia.Patients referred state-wide between March August 2021 underwent skin-prick intradermal...
Cardiovascular events remain a major cause of death in kidney transplant recipients. The optimal noninvasive workup to prevent peritransplant cardiac mortality remains contentious.We conducted retrospective analysis assess the renal transplantation cardiovascular assessment protocol within single-center population over 5-year period. Asymptomatic patients aged less than 45 years with no history cigarette smoking, without diabetes mellitus, and dialysis-dependent for 24 months did not undergo...
Background: Cardiovascular (CV) events remain a major cause of death in kidney transplant recipients and an accurate CV risk assessment is required prior to patient being placed on active wait-list. Determining the optimal protocol non-invasive test modality for work-up remains contentious. The aim this study was assess used within single centre. Methods: We conducted retrospective analysis rates myocardial infarction (MI) at 30 days post renal transplantation patients who had been processed...
Introduction: Kidney transplant recipients (KTRs) are highly vulnerable to severe COVID-19, however poorly protected by vaccination. Additional vaccine doses have achieved limited improvements in serological neutralisation or T cell response. A novel strategy boost response is needed. Inhibition of mechanistic target rapamycin (mTOR) has been found enhance the formation memory cells following vaccination non-human primates. Methods: KTRs and age-matched healthy controls (HC) were recruited...
Background: Development of a safe, cost-effective and scalable betalactam allergy de-labelling strategy could improve antibiotic use.Methods: Phase 1 this observational, prospective study described outcomes current local beta-lactam practices at six sites.A modified Delphi method then determined standardised procedures for 2: minimum panel skin testing reagents if performed; addition proforma letter all participants their doctors outlining assessment results; offer free MediBand to those...